CAMP4 Therapeutics Corporation Finance Lease, Right-of-Use Asset, Amortization
CAMP4 Therapeutics Corporation (CAMP) reported Finance Lease, Right-of-Use Asset, Amortization of $7.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2025-11-06
- CAMP4 Therapeutics Corporation finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $7.00K, a 85.71% decline year-over-year.
- CAMP4 Therapeutics Corporation finance lease, right-of-use asset, amortization for the quarter ending 2025-06-30 was $13.00K, a 73.47% decline year-over-year.
- CAMP4 Therapeutics Corporation finance lease, right-of-use asset, amortization for the quarter ending 2025-03-31 was $26.00K, a 46.94% decline year-over-year.
- CAMP4 Therapeutics Corporation finance lease, right-of-use asset, amortization for the quarter ending 2024-12-31 was $43.00K, a 6.52% decline year-over-year.
- CAMP4 Therapeutics Corporation finance lease, right-of-use asset, amortization for fiscal 2024 was $189.00K, a 29.45% increase from fiscal 2023.
- CAMP4 Therapeutics Corporation finance lease, right-of-use asset, amortization for fiscal 2023 was $146.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2025-09-30 | $7.00K 10-Q · filed 2025-11-06 | $20.00K derived: sum of 2 quarters · filed 2025-11-06 | $46.00K 10-Q · filed 2025-11-06 | $89.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | $13.00K 10-Q · filed 2025-08-14 | $39.00K 10-Q · filed 2025-08-14 | $82.00K derived: sum of 3 quarters · filed 2025-08-14 | $131.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-03-31 | $26.00K 10-Q · filed 2025-05-13 | $69.00K derived: sum of 2 quarters · filed 2025-05-13 | $118.00K derived: sum of 3 quarters · filed 2025-11-06 | $167.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $92.00K derived: sum of 2 quarters · filed 2025-11-06 | $141.00K derived: sum of 3 quarters · filed 2025-11-06 | $189.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $49.00K 10-Q · filed 2025-11-06 | $98.00K derived: sum of 2 quarters · filed 2025-11-06 | $146.00K 10-Q · filed 2025-11-06 | $193.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $49.00K 10-Q · filed 2025-08-14 | $98.00K 10-Q · filed 2025-08-14 | $144.00K derived: sum of 3 quarters · filed 2025-08-14 | $185.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $49.00K 10-Q · filed 2025-05-13 | $95.00K derived: sum of 2 quarters · filed 2025-05-13 | $136.00K derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $87.00K derived: sum of 2 quarters · filed 2025-03-27 | $146.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $41.00K 10-Q · filed 2024-11-21 | $100.00K 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |